Boyce Thompson Institute for Plant Research
Contact Us   Visit Us   Careers

Technology Transfer

Overview

Technology Transfer: Ensuring that Society Benefits from BTI Research

The Boyce Thompson Institute for Plant Research makes fundamental discoveries in plant biology with support from federal and private grants. An important part of our mission is to identify basic research results that can be applied to commercial or humanitarian goals: to improve agriculture, enhance human health, or protect the environment. Discoveries with commercial potential are submitted for patent protection. By reaching out to scientists in industry, we identify opportunities for licensing, collaborative research, or consulting.

Collaborations and Consulting

The expertise of BTI scientists includes such diverse areas as plant disease and insect resistance, fundamentals of photosynthesis and abiotic stress tolerance, and genome-scale capabilities, including DNA and RNA sequencing, bioinformatics, small molecule chemistry, and functional proteomics. In addition, we have expertise in plant transformation and insect cell culture.

Discoveries Making an Impact

Seminal BTI discoveries include:

  • Vaccine or protein production in insect cell lines
  • Natural small molecules in plant and human health
  • Plant disease resistance
    • Salicylic acid pathway for systemic acquired resistance
    • Plant and bacterial proteins in innate and effector-triggered immunity
  • Plant insect resistance – plant genes and small signaling molecules
  • Plant-based vaccines

Industry Opportunities

Featured Technologies

Please follow the links below, which lead to slide decks that explain the various technologies in a clear and pictorial manner

Enabling Technologies

Emerging Technologies

BTI’s research into the viral diseases of insects leads to advances in Cancer Prevention

An insect cell line BTI-TN5B1 (The High-Five ™), developed at BTI by Dr. Robert Granados while doing basic research on insects viruses, is now being used to produce Cervarix ™ made by GlaxoSmithKline. This is one of two currently available vaccines that targets the HPV virus a major cause of cervical cancer. The vaccine is currently being used in over 100 countries around the world.

Industry Opportunities

Contact Us

Paul Debbie, MBA
Director, Technology Transfer and Licensing
ppd2@cornell.edu
607-254-8729

Donna Claes
Technology Transfer Specialist
dlm39@cornell.edu
607-254-4757